Literature DB >> 10620447

Assessment of hypermethylated DNA in two promoter regions of the estrogen receptor alpha gene in human endometrial diseases.

M Hori1, M Iwasaki, J Shimazaki, S Inagawa, M Itabashi.   

Abstract

OBJECTIVE: DNA methylation in the promoter regions of many genes is associated with the regulation of gene expression. We examined the frequency of DNA hypermethylation at two nucleotide positions, the proximal promoter region (PPR) in exon 1 and the distal promoter region (DPR) in exon 1', of the estrogen receptor alpha (ERalpha) gene in 111 cases of various human endometrial diseases.
METHODS: The degree of hypermethylation of PPR and DPR was examined by semi-quantitative competitive polymerase chain reaction assay using restriction enzymes (HpaII, NotI, and SacII).
RESULTS: Endometrial tissues in the proliferative phase obtained from patients with leiomyomas and/or adenomyosis and no significant hormonal abnormalities did not show hypermethylation at the HpaII cleavage position of DPR. In 6 of 16 (37.5%) cases of simple endometrial hyperplasia, the PPR was hypermethylated, whereas in cases of atypical endometrial hyperplasia and endometrioid adenocarcinoma the frequencies were extremely low. Hypermethylation of these promoter regions did not correlate with lack of ERalpha protein in the 46 cases that were analyzed by enzyme immunoassay.
CONCLUSIONS: ERalpha gene transcription from the distal promoter, rather than from the proximal promoter, is predominant in the proliferative phase of the normal menstrual cycle, because the PPR, but not the DPR, is frequently hypermethylated under those conditions. Conversely, ERalpha gene transcription from the proximal promoter is predominant in precancerous lesions such as atypical hyperplasia and endometrial cancer. However, hypermethylation at the promoter sites we examined was not related to the loss of ERalpha protein in endometrial disease. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10620447     DOI: 10.1006/gyno.1999.5662

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

Review 1.  Molecular and cellular determinants of estrogen receptor alpha expression.

Authors:  Joseph J Pinzone; Holly Stevenson; Jeannine S Strobl; Patricia E Berg
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

Review 2.  Epigenetic control of embryo-uterine crosstalk at peri-implantation.

Authors:  Shuangbo Kong; Chan Zhou; Haili Bao; Zhangli Ni; Mengying Liu; Bo He; Lin Huang; Yang Sun; Haibin Wang; Jinhua Lu
Journal:  Cell Mol Life Sci       Date:  2019-07-27       Impact factor: 9.261

Review 3.  The Mechanism and Function of Epigenetics in Uterine Leiomyoma Development.

Authors:  Qiwei Yang; Aymara Mas; Michael P Diamond; Ayman Al-Hendy
Journal:  Reprod Sci       Date:  2015-04-28       Impact factor: 3.060

Review 4.  DNA methylation in endometrial cancer.

Authors:  Meng Hua Tao; Jo L Freudenheim
Journal:  Epigenetics       Date:  2010-08-16       Impact factor: 4.528

5.  Loss of estrogen receptor 1 enhances cervical cancer invasion.

Authors:  Yali Zhai; Guido T Bommer; Ying Feng; Alexandra B Wiese; Eric R Fearon; Kathleen R Cho
Journal:  Am J Pathol       Date:  2010-06-25       Impact factor: 4.307

6.  ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention.

Authors:  Joseph C Baker; Julie H Ostrander; Siya Lem; Gloria Broadwater; Gregory R Bean; Nicholas C D'Amato; Vanessa K Goldenberg; Craig Rowell; Catherine Ibarra-Drendall; Tracey Grant; Patrick G Pilie; Shauna N Vasilatos; Michelle M Troch; Victoria Scott; Lee G Wilke; Carolyn Paisie; Sarah M Rabiner; Alejandro Torres-Hernandez; Carola M Zalles; Victoria L Seewaldt
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-08       Impact factor: 4.254

7.  Endometrial Endometrioid Carcinoma Metastases Show Decreased ER-Alpha and PR-A Expression Compared to Matched Primary Tumors.

Authors:  Carla Bartosch; Sara Monteiro-Reis; Renata Vieira; Armindo Pereira; Marta Rodrigues; Carmen Jerónimo; José M Lopes
Journal:  PLoS One       Date:  2015-08-07       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.